XERS — Xeris Biopharma Holdings, Inc. stock price, charts and financials
QT67Xeris Biopharma Holdings, Inc.Xeris Biopharma Holdings, Inc. (NASDAQ: XERS) is a Healthcare company in the Biotechnology industry. QuoTrend tracks its price, financials, earnings, analyst ratings and insider trades.
Latest market price
8.16
+0.38+4.88%
TA
Loading chart...
Snapshot
| Index | - | P/E | - | EPS (ttm) | -0.10 | Insider Own | 11.66% | Shs Outstand | 172.64M | Perf Week | 6.39% |
| Market Cap | 1.41B | Forward P/E | 22.80 | EPS next Y | 0.36 | Insider Trans | -1.75% | Shs Float | 164.66M | Perf Month | -7.80% |
| Enterprise Value | 1.57B | PEG | - | EPS next Q | 0.02 | Inst Own | - | Short Float | 4.88% | Perf Quarter | 18.26% |
| Income | -17.00M | P/S | 4.21 | EPS this Y | 62.00% | Inst Trans | - | Short Ratio | 4.30 | Perf Half Y | 50.28% |
| Sales | 335.00M | P/B | - | EPS next Y | 1041.74% | ROA | -4.17% | Short Interest | 8.04M | Perf YTD | 3.95% |
| Book/sh | -0.06 | P/C | 11.55 | EPS next 5Y | - | ROE | -426.33% | 52W High | 10.08 -19.05% | Perf Year | 9.24% |
| Cash/sh | 0.71 | P/FCF | 23.23 | EPS past 3/5Y | - | ROIC | 12.51% | 52W Low | 5.25 55.43% | Perf 3Y | 300.00% |
| Dividend Est. | - | EV/EBITDA | 98.17 | Sales past 3/5Y | 38.46% 70.95% | Gross Margin | 83.34% | Volatility | 4.56% 4.05% | Perf 5Y | 210.27% |
| Dividend TTM | - | EV/Sales | 4.69 | EPS Y/Y TTM | 72.97% | Oper. Margin | 10.91% | ATR (14) | 0.36 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 1.02 | Sales Y/Y TTM | 65.02% | Profit Margin | -5.12% | RSI (14) | 50.19 | Recom | 2.09 |
| Dividend Gr. 3/5Y | - | Current Ratio | 1.45 | EPS Q/Q | - | SMA20 | -1.34% | Beta | 0.70 | Target Price | 14.00 |
| Payout | 0.00% | Debt/Eq | 2.71 | Sales Q/Q | 27.78% | SMA50 | -2.04% | Rel Volume | 1.25 | Prev Close | 7.78 |
| Employees | 435 | LT Debt/Eq | 2.29 | Earnings | Nov 05 | SMA200 | 15.35% | Avg Volume | 1.88M | Price | 8.16 |
| IPO Date | Jun 21, 2018 | Option/Short | Yes / Yes | EPS/Sales Surpr. | -1582.34% 0.98% | Net Debt/EBITDA | 10.22 | Volume | 2,341,221 | Change | 4.88% |
Analyst Ratings
| Date | Action | Analyst | Rating | Target |
|---|---|---|---|---|
| Sep-10-26 | Reiterated | Leerink Partners | Outperform | $16 |
| Aug-20-26 | Reiterated | Barclays | Overweight | $9.00 → $12 |
| Dec-08-25 | Initiated | Barclays | Overweight | $9.00 |
| Oct-29-25 | Reiterated | Oppenheimer | Outperform | $5.00 → $18 |
| Mar-07-25 | Reiterated | Piper Sandler | Neutral | $3.00 → $4.00 |
| Nov-11-24 | Reiterated | HC Wainwright & Co. | Buy | $6.60 |
| Nov-11-24 | Downgrade | Piper Sandler | Overweight → Neutral | |
| Oct-23-24 | Reiterated | Oppenheimer | $5.00 | |
| May-10-24 | Reiterated | Piper Sandler | Overweight | $3.00 |
| Apr-28-22 | Reiterated | Craig-Hallum | Buy | $6.50 |
Latest News· Times ET
Sep-11-26
Sep-11-2603:19PM
Sep-09-26
Sep-09-2611:17AM
05:00AM
Aug-31-26
Aug-31-2612:31AM
Aug-26-26
Aug-26-2610:16PM
03:30AM
Xeris Announces Details for XP-8121 Program Overview Webinarbusinesswire.com
Aug-20-26
Aug-20-2608:50AM
Aug-07-26
Aug-06-26
Aug-06-2611:04AM
03:00AM
Xeris Biopharma Reports Second Quarter 2026 Financial Resultsbusinesswire.com
Jul-23-26
Jul-23-2604:00AM
Jul-08-26
Jul-02-26
Jul-02-2607:00PM
12:05PM
Company
Xeris Biopharma Holdings, Inc. operates as a biopharmaceutical company, focusing on the development and commercialization of therapeutic solutions for individuals across the fields of endocrinology, neurology, and gastroenterology. Its current portfolio includes: Gvoke: A ready-to-administer liquid glucagon designed to treat severe hypoglycemia. Keveyis: A therapy addressing hyperkalemic, hypokalemic, and related forms of primary periodic paralysis. Recorlev: A cortisol synthesis inhibitor approved for managing endogenous hypercortisolemia in adult patients with Cushing's syndrome. Beyond its marketed products, the company maintains an active development pipeline. This pipeline seeks to broaden the applications and indications for existing treatments and introduce novel pharmaceuticals leveraging its proprietary XeriSol and XeriJect formulation technology platforms. Founded in 2005, Xeris Biopharma is headquartered in Chicago, Illinois.
Ownership
Per-holder 13F data hasn't been ingested for this ticker yet.
Financial Statements
DataTimeframe
| Line Item (USD, M) | TTM — | FY 2025 12/31/2025 | FY 2024 12/31/2024 | FY 2023 12/31/2023 | FY 2022 12/31/2022 | FY 2021 12/31/2021 | FY 2020 12/31/2020 | FY 2019 12/31/2019 | FY 2018 12/31/2018 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 335 | 292 | 203 | — | — | — | — | — | — | |
| Cost of Goods Sold Incl. D&A | 56 | 53 | 37 | — | — | — | — | — | — | |
| Gross Profit | 280 | 238 | 166 | — | — | — | — | — | — | |
| Selling, General and Administrative Excl. Other | 208 | 182 | 163 | — | — | — | — | — | — | |
| Research and Development | 35 | 31 | 26 | — | — | — | — | — | — | |
| Other Operating Expense | 0 | 1 | 11 | — | — | — | — | — | — | |
| Operating Income | 37 | 25 | -34 | — | — | — | — | — | — | |
| Interest Expense | 28 | 29 | 33 | — | — | — | — | — | — | |
| Unusual Expense | — | — | — | — | — | — | — | — | — | |
| Non-Operating Income (Expense) | -26 | 5 | 10 | — | — | — | — | — | — | |
| Net Income Before Taxes | -17 | 1 | -57 | — | — | — | — | — | — | |
| Income Taxes | 0 | 0 | -2 | — | — | — | — | — | — | |
| Consolidated Net Income | -17 | 1 | -55 | — | — | — | — | — | — | |
| Net Income From Continuing Operations | -17 | 1 | -55 | — | — | — | — | — | — | |
| Net Income | -17 | 1 | -55 | — | — | — | — | — | — | |
| EPS (Recurring) | -0.10 | 0.00 | -0.37 | — | — | — | — | — | — | |
| EPS (Basic, Before Extraordinaries) | -0.10 | 0.00 | -0.37 | — | — | — | — | — | — | |
| EPS (Diluted) | -0.10 | 0.00 | -0.37 | — | — | — | — | — | — | |
| EBITDA | 16 | 13 | -14 | — | — | — | — | — | — | |
| Other After Tax Adjustments | — | — | — | — | — | — | — | — | — | |
| Stock Option Compensation Expense | — | — | — | — | — | — | — | — | — | |
| Price To Earnings Ratio | — | 2,453.12 | — | — | — | — | — | — | — | |
| Price To Sales Ratio | 4.21 | 4.30 | 2.45 | — | — | — | — | — | — | |
| Gross Margin | 83.58 | 81.51 | 81.77 | — | — | — | — | — | — | |
| Operating Margin | 11.04 | 8.56 | -16.75 | — | — | — | — | — | — | |
| Net Margin | -5.07 | 0.34 | -27.09 | — | — | — | — | — | — | |
| Shares Outstanding | 173 | 160 | 147 | — | — | — | — | — | — | |
| Market Capitalization | 1,412 | 1,256 | 498 | — | — | — | — | — | — | |
| Operating Lease Expense | — | — | — | — | — | — | — | — | — |
Unlock full historical data
See years of past statements with Premium.
Insider Trading Volume
Insider Trading
| Insider | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|
| Hecht Beth | See Remarks | Sep 01 '26 | Sale | 8.49 | 16,666 | 141,434 | 1,127,796 | Sep 01 |
| McCulloch Kevin | See Remarks | Sep 01 '26 | Sale | 8.49 | 15,000 | 127,308 | 1,639,208 | Sep 01 |
| Pieper Steven | See Remarks | Sep 01 '26 | Sale | 8.50 | 5,000 | 42,500 | 1,356,053 | Sep 01 |
| Pieper Steven | See Remarks | Aug 12 '26 | Sale | 8.50 | 5,000 | 42,500 | 1,361,053 | Aug 12 |
| Hecht Beth | See Remarks | Aug 03 '26 | Sale | 8.01 | 16,666 | 133,553 | 1,144,462 | Aug 04 |
| McCulloch Kevin | See Remarks | Aug 03 '26 | Sale | 8.02 | 15,000 | 120,240 | 1,676,126 | Aug 04 |
| Pieper Steven | See Remarks | Jul 07 '26 | Sale | 8.52 | 27,600 | 235,276 | 1,366,053 | Jul 07 |
| Pieper Steven | See Remarks | Jul 06 '26 | Sale | 8.50 | 17,400 | 147,900 | 1,393,653 | Jul 07 |
| McCulloch Kevin | See Remarks | Jul 01 '26 | Sale | 8.03 | 90,000 | 722,511 | 1,691,126 | Jul 02 |
| Hecht Beth | See Remarks | Jul 01 '26 | Sale | 8.03 | 16,666 | 133,860 | 1,161,128 | Jul 02 |
| JOHNSON JOHN | Director | Jun 04 '26 | Sale | 6.09 | 15,000 | 91,422 | 683,083 | Jun 05 |
| HALKUFF DAWN | Director | Jun 04 '26 | Sale | 6.09 | 20,000 | 121,886 | 95,000 | Jun 05 |
| BORMANN-KENNEDY BARBARA-JEAN ANNE | Director | Jun 04 '26 | Sale | 6.09 | 16,000 | 97,507 | 126,500 | Jun 05 |
| PERSKY MARLA | Director | Jun 03 '26 | Sale | 5.90 | 15,500 | 91,433 | 126,500 | Jun 05 |
| Hecht Beth | See Remarks | Jun 01 '26 | Sale | 6.06 | 16,667 | 100,982 | 1,176,506 | Jun 02 |
QuoTrend signals describe historical patterns and statistics — educational information, not investment advice or a recommendation to buy or sell. Past performance doesn’t guarantee future results. Every figure traces to QuoTrend data. Historical patterns — not a prediction or advice.